Figure S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Supplementary Figure S3. Viability with niraparib and olaparib in additional clones – related to Figure 2. A) Immunoblotting analysis of POLB from 2 individual clones confirming POLB knockout in BRCA1 mutant MDA-MB-436 (left) and SUM149PT cells (right). Cl#1 of sgIntron and cl#3 of sgPOLB for MDA-MB-436 and cl#1 of sgIntron and cl#1 of sgPOLB for SUM149PT are same as in Fig. 2A. B) Dose response curves of control (cl#1) and POLB knockout (cl#5) derivatives of MDA-MB436 cells treated with niraparib (left) and dose response curves of control (cl#1) and POLB knockout (cl#2) derivatives of SUM149PT cells treated with niraparib (middle) and olaparib (right) for 7 days. Data are represented as mean +SD, N = 3. Statistical significance was derived from nonlinear regression curves of sgIntron vs. sgPOLB (****, P